Vincent Y. Ling

His practice focuses on intellectual property litigation at both the trial and appellate levels, particularly in patent infringement and trade secret misappropriation matters.

Mr. Ling has substantial trial experience, trying cases to jury verdict in numerous district courts, including the District of Delaware, Northern District of California, Central District of California, and Eastern District of Texas. He has also helped secure significant appellate victories, including the reversal of a jury verdict of over $1.2 billion on behalf of Kite Pharma, Inc., a subsidiary of Gilead Sciences, in litigation over the cancer treatment Yescarta®. He has represented both plaintiffs and defendants in high stakes litigation across a range of industries, including biopharmaceuticals, wireless communications, and semiconductor and computer technologies.

In 2020, Mr. Ling was selected as a Pathfinder for the Leadership Council on Legal Diversity (LCLD). The LCLD Pathfinder program’s focus is to help increase diversity at the leadership levels of the nation’s law firms. He is also on the board of the Judge Paul R. Michel Intellectual Property American Inn of Court; was past chair of the Patent and Trade Secret Committee of the Los Angeles Intellectual Property Law Association (LAIPLA); and is an active member of the Federal Circuit Bar Association. He has also authored articles on legal topics for Law 360, Intellectual Property Magazine, and the American Bar Association.

Mr. Ling joined the firm after clerking with Chief Judge Sharon Prost of the U.S. Court of Appeals for the Federal Circuit. Prior to his clerkship, he was an associate in the New York office of an international law firm, where he focused on intellectual property litigation. He also clerked for Judge Kent A. Jordan of the U.S. Court of Appeals for the Third Circuit and Judge Sue L. Robinson of the U.S. District Court for the District of Delaware. During law school, he served as a legal writing instructor.